Metsera, Inc.

Metsera, Inc.

MTSR·NASDAQ

$70.50

+0.0000%
HealthcareBiotechnology

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$7.43B
EPS-2.0300
P/E Ratio-34.73
Earnings Date03/25/2026

mtsr

Prepaids

Last Annual Value

2.06M

3-Year CAGR

34%

5-Year CAGR

19%

10-Year CAGR

9%

Metsera, Inc.

Metsera, Inc. Competitors Analysis of Prepaids

MTSR · NASDAQ
CompanyPrepaids
CAGR 3Y
CAGR 5Y
CAGR 10Y
MTSR logo
Metsera, Inc.
NASDAQ:MTSR
2.06M
34.3%N/AN/A 
10.93M
7.4%20.2%23.8%
ACLX logo
Arcellx, Inc.
NASDAQ:ACLX
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
NUVL logo
Nuvalent, Inc.
NASDAQ:NUVL
20.47M
N/A52.1%N/A
16.17M
92.7%14.0%44.0%
PCVX logo
Vaxcyte, Inc.
NASDAQ:PCVX
17.04M
40.4%10.4%N/A
Metsera, Inc.

Metsera, Inc. Fair Value Envelope

MTSR · NASDAQ

Our analysis suggests that MTSR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $70.5, this represents a potential HIDDEN relative to our calculated worth for Metsera, Inc..

Intrinsic Value
Current Price: $70.5